The United Kingdom and the United States have announced a landmark bilateral deal that will preserve no levies on British medicine shipments going into the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has committed to boost funding on drugs through the National Health Service (NHS). This commitment guarantees that tariffs on these key exports will stay at zero for a period of three years.
This deal comes after earlier threats to hike tariffs on branded drug imports, with figures floated as high as one hundred percent.
"This deal with the United Kingdom bolsters the worldwide climate for new treatments and introduces much-needed equity to transatlantic medicine commerce," a statement said.
Economic Significance
Drugs are one of the the United Kingdom's biggest goods shipped to the US, which is by far the biggest market for major British pharmaceutical firms.
Export figures show that in the year prior to the third quarter, the UK sold medicines valued at over eleven billion pounds to the US. This value made up 17.4% of total UK exports in that span.
"This agreement safeguards jobs, stimulates investment and paves the way for the UK to establish itself as a worldwide center for medical research," a government official commented.
Detailed UK Commitments
The agreement involves several specific changes from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to raise total public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Payback Limit: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at 15%. Previously, repayments topped twenty percent.
Industry Background
The pact comes amid a long-running row between the sector and the UK government over spending levels and NHS adoption.
These tensions were intensified by assertions that American customers were paying a premium for the same drugs than patients in the UK and Europe.
In recent months, several large pharmaceutical investments in the UK have been paused or scrapped, while major investments have been pledged toward American operations.
One official acknowledged that the NHS must invest a greater share on treatments, noting that its spending on drugs had decreased as a percentage of its overall budget over the previous ten-year period.
